Haemonetics Corp. (NYSE:HAE) was downgraded by analysts at CJS Securities from a “market outperform” rating to a “market perform” rating in a research report issued on Tuesday.

Several other equities research analysts also recently commented on HAE. Barrington Research downgraded shares of Haemonetics Corp. from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 3rd. Jefferies Group increased their price target on shares of Haemonetics Corp. from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, August 2nd. Zacks Investment Research downgraded shares of Haemonetics Corp. from a “hold” rating to a “sell” rating in a report on Wednesday, August 3rd. Benchmark Co. increased their price target on shares of Haemonetics Corp. from $28.00 to $32.00 and gave the stock a “hold” rating in a report on Tuesday, August 2nd. Finally, Sidoti downgraded shares of Haemonetics Corp. from a “buy” rating to a “neutral” rating and set a $39.00 price target on the stock. in a report on Monday, August 15th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the stock. Haemonetics Corp. has an average rating of “Hold” and a consensus target price of $34.40.

Analyst Recommendations for Haemonetics Corp. (NYSE:HAE)

Shares of Haemonetics Corp. (NYSE:HAE) opened at 37.16 on Tuesday. Haemonetics Corp. has a 12-month low of $25.98 and a 12-month high of $38.06. The company’s market capitalization is $1.91 billion. The firm’s 50-day moving average is $36.39 and its 200-day moving average is $32.25.

Haemonetics Corp. (NYSE:HAE) last released its quarterly earnings data on Monday, August 1st. The company reported $0.25 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.28 by $0.03. The business had revenue of $210 million for the quarter, compared to analysts’ expectations of $205.41 million. Haemonetics Corp. had a negative net margin of 7.25% and a positive return on equity of 10.75%. Haemonetics Corp.’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period last year, the company earned $0.35 earnings per share. On average, equities analysts predict that Haemonetics Corp. will post $1.44 EPS for the current year.

In related news, Director Ronald Merriman sold 4,337 shares of the firm’s stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $35.14, for a total value of $152,402.18. Following the sale, the director now directly owns 22,088 shares of the company’s stock, valued at $776,172.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Christopher Simon bought 60,000 shares of the stock in a transaction that occurred on Thursday, August 4th. The stock was bought at an average cost of $35.00 per share, for a total transaction of $2,100,000.00. The disclosure for this purchase can be found here. 1.50% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the stock. Louisiana State Employees Retirement System increased its stake in shares of Haemonetics Corp. by 0.4% in the second quarter. Louisiana State Employees Retirement System now owns 22,600 shares of the company’s stock worth $655,000 after buying an additional 100 shares in the last quarter. Profund Advisors LLC boosted its position in shares of Haemonetics Corp. by 0.9% in the second quarter. Profund Advisors LLC now owns 13,954 shares of the company’s stock worth $405,000 after buying an additional 124 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Haemonetics Corp. by 0.6% in the second quarter. JPMorgan Chase & Co. now owns 34,619 shares of the company’s stock worth $1,003,000 after buying an additional 201 shares during the last quarter. PineBridge Investments L.P. boosted its position in shares of Haemonetics Corp. by 4.2% in the second quarter. PineBridge Investments L.P. now owns 6,473 shares of the company’s stock worth $187,000 after buying an additional 261 shares during the last quarter. Finally, Fox Run Management L.L.C. boosted its position in shares of Haemonetics Corp. by 3.8% in the second quarter. Fox Run Management L.L.C. now owns 8,200 shares of the company’s stock worth $238,000 after buying an additional 300 shares during the last quarter. 98.64% of the stock is currently owned by institutional investors and hedge funds.

About Haemonetics Corp.

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

5 Day Chart for NYSE:HAE

Receive News & Ratings for Haemonetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.